[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355374-105":59,"doc-detail-355374-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","evaluation-of-loss-of-the-y-chromosome-in-peripheral-blood-as-a-biomarker-for-prostate-cancer","Evaluation of Loss of the Y Chromosome in Peripheral Blood as a Biomarker for Prostate Cancer","","Prostate cancer remains common among men, yet prostate-specific antigen (PSA) testing provides limited diagnostic accuracy. This study evaluates loss of the Y chromosome (LOY) as a potential diagnostic biomarker to improve prostate cancer detection and clinical decision-making. LOY was quantified using droplet digital PCR and risk prediction models were assessed with logistic regression and bootstrapping validation. Results show higher LOY in cancer versus normal groups and improved model performance (AUC 0.898).",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evaluation-of-loss-of-the-y-chromosome-in-peripheral-blood-as-a-biomarker-for-prostate-cancer/355374/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evaluation-of-loss-of-the-y-chromosome-in-peripheral-blood-as-a-biomarker-for-prostate-cancer/355374.png","ImageObject",300,407,{"name":92,"@type":93},"Jacob","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is PSA considered insufficient for prostate cancer diagnosis?","Question",{"text":113,"@type":114},"PSA testing is widely used but has limited diagnostic accuracy, leading to imperfect risk assessment and potentially unnecessary biopsies and treatments.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was LOY measured in this study?",{"text":118,"@type":114},"LOY levels were measured using droplet digital polymerase chain reaction (ddPCR), integrating clinical indicators to evaluate clinical relevance.",{"name":120,"@type":111,"acceptedAnswer":121},"What diagnostic performance did LOY achieve for prostate cancer?",{"text":122,"@type":114},"LOY showed significantly higher levels in the cancer group than the normal group and demonstrated diagnostic efficacy with AUC = 0.898, with added clinical benefit when incorporated into conventional models.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355374,1790832510,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","The Prostate   \nORIGINAL ARTICLE   \nEvaluation of Loss of the Y Chromosome in Peripheral Blood as a Biomarker for Prostate Cancer  \nJun Lu1  | Yan Lu1 | Takuro Kobayashi1,2,3  | Tsuyoshi Hachiya2,4  | Haruhiko Wakita1 | Yiming Jin1 | Yasunari Tanaka1 | Yoshihiro Ikehata1,2 | Masayoshi Nagata1 | Hisamitsu Ide1,4 | Shigeo Horie1,2,4  \n1Department of Urology, Juntendo University, Graduate School of Medicine, Tokyo, Japan | 2Data Science and Informatics for Genetic Disorders, Graduate School of Medicine, Juntendo University, Tokyo, Japan | 3Hematovascular Biology Center, Division of Cardiovascular Medicine and Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, Virginia, USA | 4Department of Innovative Longevity, Graduate School of Medicine, Juntendo University, Tokyo, Japan  \nCorrespondence: Hisamitsu Ide ([h.ide.me@juntendo.ac.jp](h.ide.me@juntendo.ac.jp))  \nReceived: 22 September 2025 | Revised: 4 December 2025 | Accepted: 13 January 2026  \nFunding: KAKENHI (Grants‐in‐Aid for Scientific Research) from the Japan Society for the Promotion of Science (JSPS), Grant/Award Number: 24K12476  \nKeywords: biomarkers | diagnosis | LOY | prostate cancer | PSA  \nABSTRACT  \nBackground: Prostate cancer (PCa) is the most common malignant tumor in men, but the widely used prostate‐specific antigen (PSA) test has limited diagnostic accuracy. Research proposes that the loss of the Y chromosome (LOY) may affect the occurrence and development of prostate cancer, aiming to assess its potential as a diagnostic biomarker to improve the accuracy of prostate cancer detection and clinical management.  \nMethods: LOY levels were measured using droplet digital polymerase chain reaction (ddPCR) method, integrating relevant clinical indicators to evaluate the potential clinical significance of LOY in PCa. Logistic regression was employed to estimate risk prediction capability of LOY, and model performance was validated through bootstrapping.  \nFindings: 131 men patients were enrolled in this study whose PSA level exceeding 4.0 ng/ml and underwent prostate biopsies. According to post‐biopsy pathological results, subjects were classified into normal and cancer groups. LOY levels were significantly higher in the cancer group than in the normal group (p \u003C 0.001) . LOY levels show a consistent increase with advancing AJCC clinical stage and escalating PI‐RADS scores. LOY is a promising biomarker for PCa (AUC = 0.898) . Clinical decision curve analyzes demonstrated that incorporating LOY into each conventional model provided greater clinical benefit compared with the original model.  \nInterpretation: In biopsy patients, the LOY levels in the cancer group were higher than those in the normal group, and this was more pronounced in patients at advanced clinical stages. LOY levels have strong diagnostic efficacy for PCa, indicating that LOY may serve as an auxiliary biomarker for early PCa diagnosis.  \n\n| Abbreviations: AJCC stage, American Joint Committee on Cancer stage; AMEL, amelogenin; AUC, area under the curve; BMI, body mass index; CI, confidence interval; cNRI, category‐free NRI; CNV, copy number variation; ddPCR, droplet digital polymerase chain reaction; FISH, fluorescent in situ hybridization; GS, Gleason score; GWAS, genome‐wide association studies; IDI, integrated discrimination improvement; LOY, loss of the Y chromosome; NGS, next‐generation sequencing; NRI, net reclassification index; OR, odds ratio; PCa, prostate cancer; PI‐RADS score, prostate Imaging‐Reporting and Data System score; PSA, prostate‐specific antigen;\u003Cbr>QF‐PCR, multiplexquantitative fluorescence polymerase chain reaction; ROC curves, receiver operating characteristic curves; WGS, whole gene sequencing. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is ","cbCaihPx8s4LKE0s","https://ap.wps.com/l/cbCaihPx8s4LKE0s","pdf",1275618,11,"English","# Abstract\n## Background\n## Methods\n## Findings\n## Interpretation\n# Introduction\n## Clinical context and limitations of PSA","[{\"question\":\"Why is PSA considered insufficient for prostate cancer diagnosis?\",\"answer\":\"PSA testing is widely used but has limited diagnostic accuracy, leading to imperfect risk assessment and potentially unnecessary biopsies and treatments.\"},{\"question\":\"How was LOY measured in this study?\",\"answer\":\"LOY levels were measured using droplet digital polymerase chain reaction (ddPCR), integrating clinical indicators to evaluate clinical relevance.\"},{\"question\":\"What diagnostic performance did LOY achieve for prostate cancer?\",\"answer\":\"LOY showed significantly higher levels in the cancer group than the normal group and demonstrated diagnostic efficacy with AUC = 0.898, with added clinical benefit when incorporated into conventional models.\"}]","Evaluation of Loss of the Y Chromosome in Peripheral Blood as a Biomarker for Prostate Cancer | PDF",1790118186,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98f3efaba0aad3450b57245934080b51.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ddd8111bdfa4f25704451268692b340d.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef9b50a9a24faac3358bb34618aadc6c.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e01f6c6b9466ba75c9b270d4d2998155.webp",980,1287]